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In recent years,medication-related osteonecrosis of the jaw (MRONJ) became an arising disease due to the important antiresorptive
drug prescriptions to treat oncologic and osteoporotic patients, as well as the use of new antiangiogenic drugs such as VEGF
antagonist. So far, MRONJ physiopathogenesis still remains unclear. Aiming to better understand MRONJ physiopathology, the
(rst objective of this review would be to highlight major molecular mechanisms that are known to be involved in bone formation
and remodeling. Recent development in MRONJ pharmacological treatments showed good results; however, those treatments are
not curative and could have major side e)ects. In parallel to pharmacological treatments, MSC gra*s appeared to be bene(cial in
the treatment of MRONJ, in multiple aspects: (1) recruitment and stimulation of local or regional endogenous cells to di)erentiate
into osteoblasts and thus bone formation, (2) bene(cial impact on bone remodeling, and (3) immune-modulatory properties that
decrease in,ammation. In this context, the second objective of this manuscript would be to summarize the molecular regulatory
events controlling osteogenic di)erentiation, bone remodeling, and osteoimmunology and potential bene(cial e)ects of MSC
related to those aspects, in order to apprehend MRONJ and to develop new therapeutic approaches.
1. Introduction
In 2014, the American Association of Oral and Maxillo-
facial Surgeons (AAOMS) has updated the de(nition of
bisphosphonate-related osteonecrosis of the jaw (BRONJ) [1],
given the increasing number of osteonecrosis of the jaw cases
reported in patients treated with bisphosphonates (BPs).
However, since this clinical condition is also encountered
in patients treated with denosumab or other antiangiogenic
drugs [2–4], the term “medication-related osteonecrosis of
the jaw” (MRONJ) should be favored. MRONJ is de(ned
by three features: (1) current or previous treatment with
antibone resorptive or antiangiogenic agents, (2) exposed
bone or bone that can be probed through an intraoral or
extraoral (stula in the maxillofacial region that stays for
longer than 8 weeks, and (3) no previous history of radiation
therapy or obvious metastatic disease towards the jaws [1].
In osteoporotic patients, the incidence of MRONJ is 1.04
to 69 per 100,000 patient-years if treated by oral BPs, 0 to
90 per 100,000 patient-years if treated by i.v. BPs, and 0 to
30,2 per 100,000 patient-years if treated by denosumab [5–
7]. In oncologic patients, the incidence of MRONJ is 0 to
12,222 per 100,000 patient-years if treated by i.v. BPs and 0 to
2,316 per 100,000 patient-years if treated by denosumab [5–7].
Risk factors for MRONJ are multiples; the major ones are i.v.
BPs (depending on dose and duration), Zoledronate, dental
extraction, dental or periodontal disease, glucocorticoid,
chemotherapy, smoking, and obesity [8, 9].
MRONJ is two times more frequent in the mandible
than in the maxilla [10]. 'e most accepted clinical staging
system for MRONJ has been developed by Ruggiero and
colleagues and has been adopted by the AAOMS [1]. 'is
clinical scale describes (ve stages: at risk, 0, 1, 2, and 3. Stage
“at risk” includes patients undergoing treatment with oral
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Table 1: Drugs demonstrated to be implied in the triggering of the jaw osteonecrosis: name, mode of action or molecular target, and
therapeutic indications.




Nonhydrolysable cytotoxic analogs of ATP





Denosumab Monoclonal antibody that inactivates RANKL OsteoporosisTumor-associated osteolysis
Bevacizumab Monoclonal antibody that inactivates VEGF
Glioblastoma
Metastatic cancers:
breast, renal, lung, colorectal
Sunitinib, Sorafenib,
Cabozantinib Tyrosine kinase inhibitors that block VEGF receptor
Metastatic cancers:





or intravenous nitrogen-containing BPs, with no evidence of
necrotic bone. Stage 0 includes patients presenting nonspe-
ci(c clinical (ndings, radiographic changes, and symptoms
with no clinical evidence of bone necrosis. Stage 1 includes
asymptomatic patients presenting an exposed and necrotic
bone or (stulae. Stage 2 includes symptomatic patients (pain,
erythema, and signs of infection) presenting an exposed and
necrotic bone or (stulae. Stage 3 includes stage 2 patients with
one of the following: (1) bone lesions extending beyond the
region of the alveolar bone resulting in pathologic fracture,
extraoral (stula, or oroantral/oronasal communication or (2)
osteolysis extending to the inferior border of the mandible or
sinus ,oor.
In this review, a*er considering drugs that have been
shown to be responsible of MRONJ, we will brie,y comment
on current physiopathological hypotheses that could explain
this particular clinical situation. We will then review several
putative treatments, with a deeper focus on cellular therapy
protocols, including (1) drug-based manipulation of bone
marrow stem cells and (2) mesenchymal stem cell (MSC)
gra*s, which are both experimental therapeutic approaches
currently used to treat this incapacitating clinical situation.
Aiming to better understand MRONJ physiopathology, we
will also summarize molecular mechanisms that are known
to be involved in bone formation and remodeling, as well as
MSC involvement in these processes. Finally, we will discuss
the link between bone homeostasis and the immune system,
referred to as “osteoimmunology.” Indeed, the MSC e)ect
could also include a modulation of this osteoimmunological
homeostasis, explaining their therapeutic e)ects.
2. Drugs-Related Osteonecrosis of the Jaw
Antiresorptive and antiangiogenic drugs were previously
shown as implied in the development of MRONJ [2–4]
(Table 1). Antiresorptive drugs (bisphosphonate and deno-
sumab) are monoclonal antibodies directed against Receptor
Activator of Nuclear Factor Kappa-B Ligand (RANKL).
Antiangiogenic drugs (Sunitinib! and Bevacizumab!) are
humanized monoclonal antibodies directed against several
activated receptors tyrosine kinase (i.e., VEGFR (vascular
endothelial growth factor receptor)).
(A) Bisphosphonates (BPs) are used to treat a wide vari-
ety of diseases characterized by excessive osteoclast-
mediated bone resorption, such as tumor-associated
osteolysis, Paget’s disease, hypercalcemia of malig-
nancy, and osteoporosis [7]. BPs are stable and
nonhydrolysable analogs of pyrophosphates that are
composed of a carbon atom linked to two phospho-
nate groups (P–C–P) to mimic the pyrophosphate
molecular structure (P–O–P). Simple BPs (SBPs)
(etidronate and clodronate) should be distinguished
from nitrogen-BPs (N-BPs) (pamidronate, alen-
dronate risedronate, ibandronate, and Zoledronate)
because of the presence of nitrogen on the side chains
of the latter. 'is structural di)erence has an impact
on the mechanism of action. Indeed, in addition to
their analog e)ect, only SBPs are metabolized into
intracellular and nonhydrolysable cytotoxic analogs
of ATP, which accumulate in the osteoclasts and
trigger their apoptosis [17]. In contrast, N-BPs inhibit
osteoclast function only by acting as potent inhibitors
of the enzyme farnesyl-diphosphate (FPP) synthase in
the cholesterol (or mevalonate) biosynthetic pathway.
'is inhibition is responsible of a decrease of GTPase
activity in cytoskeletal rearrangement and vesicu-
lar tra4cking in osteoclasts [18]. N-BPs might also
have an e)ect on the immune system, especially on
macrophages and monocytes, but this e)ect remains
controversial [19]. It has also to be noted that N-
BPs are 100 to 10,000 times more potent than SBPs
[20].More recently, it has been demonstrated that BPs
(alendronate and Zoledronate!) induce osteogenic
gene expression, such as bone morphogenic protein-
2 (BMP-2), osteocalcin, and alkaline phosphatase in
endothelial and mesenchymal stem cell [21].
(B) Denosumab is a recent antiresorptive drug that
showed better results than alendronate in improving
bone mineral density in di)erent skeletal sites [22].
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Figure 1: Two MRONJ pathogenesis theories: inside-outside and outside-inside theory.
'is human monoclonal antibody targets the Recep-
tor Activator of Nuclear Factor Kappa-B Ligand
(RANKL) [23]. In humans, bone remodeling depends
on a balance between osteoprotegerin (OPG) and
RANKL that are both produced by osteoblasts
(see molecular signaling controlling bone remodel-
ing section below). RANKL binds to its receptor
(RANK) expressed by preosteoclasts and osteoclasts
and induces, respectively, their full di)erentiation
and activation. OPG and denosumab have the same
mechanism of action: they bind to RANKL, then
blocking its interaction with RANK, inhibiting the
osteoclast maturation, function, and survival, and
reducing bone resorption [23].
(C) An increasing number of MRONJ cases are now
reported in patients treatedwith antiangiogenic drugs
[20].'ese drugs are VEGF antagonists and might be
divided into two categories: (1) monoclonal antibod-
ies that bind VEGF and, thereby, neutralize its bio-
logical activity (Bevacizumab) and (2) small molecule
tyrosine kinase inhibitors (TKIs) that block the
VEGF receptor and its downstream signaling path-
ways (Sunitinib, Sorafenib!, Cabozantinib!). VEGF
antagonists are used to treat metastatic cancer such
as renal, colorectal, lung, and breast carcinomas
[20]. Inhibitors of mammalian target of rapamycin
(mTOR) (Everolimus! and Temsirolimus!) are recent
therapeutic agents used in the treatment of metastatic
renal carcinoma.'ese drugs have also been reported
as MRONJ inducers in two case reports [24, 25].
3. Pathogenesis of MRONJ
'e pathogenesis of MRONJ has been studied for multiple
years but still remains unresolved. However, two theories are
emerging (Figure 1). 'e (rst one, called “inside-outside,”
is based on an inhibition of the osteoclastic activity and a
bone turnover decrease, both conditions induced by previ-
ously mentioned drugs. 'is decrease in bone remodeling
despite the jaw microdamage induced by chewing and local
in,ammation results in a constant exposition of bone to
high concentrations of various pathogenic microorganisms
(Figure 1(a)). 'ese conditions would lead to bone tissue
death and then to bone exposure [26]. In various ONJ
(Osteonecrosis of the Jaws) animal models, it has been
reported several times that most of the specimens present
4 Stem Cells International
a histological osteonecrosis, but only a minority of them
show an exposed bone (not covered by epithelium) [27, 28].
Another histological study of ONJ lesions in humans also
concluded that bone necrosis precedes the clinical onset and
is then responsible of an in,ammation-associated process
[29]. All of these (ndings suggest thus that bone exposure
could not be a prerequisite for bone necrosis. Moreover, the
fact that two di)erent antiresorptive drugs (BPs and deno-
sumab) with di)erent mechanisms of action are implied into
MRONJunderlines the central role played by bone resorption
inhibition inmechanically stressed jaws.'is possible central
role of bone resorption inhibition in the physiopathology of
MRONJ is also strengthened by encouraging results reported
for Teriparatide! drug, a recombinant human parathyroid
hormone that stimulates osteoclast activity [30]. All these
observations corroborate the bone resorption inhibition
theory as the etiology of MRONJ. However, there is so far
no reported case of ONJ in patients with a reduced bone
turnover condition, such as hypoparathyroidism.
'e second theory, named “outside-inside,” is based on a
local immune-depression, probably caused by BPs or deno-
sumab associated with mucosal/dental lesions that would
lead to a local infection and/or in,ammation spreading to
the bone and, there, inducing the osteonecrosis (Figure 1(b)).
It has been established that dental diseases are an important
risk factor in MRONJ: the e4cient prevention of MRONJ
in patients with cancer is observed by improvements in
their dental hygiene [31]. It is also important to highlight
that most of the tooth extractions were done because of an
existing periodontal or periapical disease [32]. Recent studies
also demonstrated that periodontal or periapical diseases
associatedwith i.v. BPs could causeMRONJ in animalmodels
[27, 28]. Finally, it has been reported that exposed bone areas
in MRONJ are recovered by a complex bio(lm with multiple
microorganisms which could explain therapy failures [33].
'e reason why medication-related osteonecrosis specif-
ically a)ects the jaw is still unknown, but some clues can be
pointed out.'e jaw is one of the least-protected bones from
infection in the human skeleton. Indeed, the mandibular and
maxilla bones are just separated from the pathogens of the
oral mucosal lesion by a thin mucoperiosteal cover, whereas
deep so* tissues and skin protect other bones. Moreover, jaw
is subjected to repeated microtraumas due to the presence
of teeth and the force of mastication. Indeed, the alveolar
bone turnover is 10-fold greater than in the long bones which
could justify the fact that alveolar bone could incorporate
much more BPs than other skeleton sites [34]. Finally, the
jaw has a speci(c embryologic development. It arises from
neural-crest cells which form at the border of the neural tube
during neurulation, and not from the mesoderm like other
bone cells of the body [35]. Furthermore, in a recent study
[36], it has been demonstrated that jaw bone defects could be
healed through neural-crest cell recruitment.
For an unknown reason, it appears that tissue home-
ostasis in the mandibular and maxilla bones is disrupted
in MRONJ patients, by the combination of (1) drugs acting
more or less on bone turnover, (2) the proximity of a highly
septic environment, and (3) the mechanical stress induced
by chewing several times a day. 'is misbalance in tissue
homeostasis leads to necrosis, which itself increases and/or
maintains this misbalance, triggering a vicious circle. Treat-
ments should therefore address this misbalance by acting
on regenerative processes, in attempt to reequilibrate this
compromised situation.
A clear understanding ofMRONJ pathogenesis ismanda-
tory before considering any therapeutic perspective. We sug-
gest three potential etiologies: (1) the lack of bone formation
caused by the absence of osteogenic di)erentiation from
MSC, (2) the imbalance in bone remodeling caused by BPs or
denosumab, and (3) the homeostasis disruption between the
immune system and bone which refers to the new concept
of osteoimmunology. In the next few paragraphs, we will
therefore focus on the molecular patterns that underlie these
potential etiologies.
3.1. Molecular Signaling Pathways Controlling Osteogenic Dif-
ferentiation. During development, bone formation begins
with MSCs aggregation and, then, cells di)erentiate sequen-
tially into chondrocytes and osteoblasts during endochon-
dral ossi(cation [14]. A*er condensation, MSCs could also
directly di)erentiate into osteoblasts in a process called
“membranous bone ossi(cation.” Sox9 and Run-related tran-
scription factor 2 (Runx2) are two essential transcription
factors expressed in MSCs during osteoblast di)erentiation.
Sox9 induces cell condensation which is precluding their
conversion and di)erentiation into chondrocytes [37]. Runx2
stimulates chondrocyte proliferation and growth into larger
cells and then into osteoblasts [38]. Besides this intracellular
signalization, there are (ve extracellular pathways that are
identi(ed in osteoblastogenesis as summarized in Figure 2:
(1) Ihh, (2) PTH and PTHrp, (3) BMP, (4) Wnt-훽 catenin
canonical, and (5) MAPK pathways.
During fetal bone formation, MSCs are recruited. Runx2
expression is then activated, which induces MSCs di)erenti-
ation into osteochondroblast progenitors [38] (Figure 3(a)).
In this early stage, mostly Ihh pathway activates Runx2. At
later stage, BMPs and MAPK pathways stimulate Runx2 but
alsoDlx5 expression.Dlx5 is an osteogenic homeobox protein
involved in osteoblasts maturation [39]. Depending on Dlx5
levels, Msx2, another osteogenic homeobox protein, induces
immature cell proliferation.
Osteochondroblast progenitors (Runx2+, Dlx5+, and
Msx2+ cells) mature into committed preosteoblast cells,
which express osterix (Osx), collagen 1훼1 (Col1훼1), alkaline
phosphatase (ALP), and PTH-R1. Osterix is a transcriptional
factor acting as an essential regulator of late osteogenesis
through the inhibition of chondrogenesis [40]. 'is process
of maturation for osteochondroblast is induced by BMP and
Wnt canonical pathways. Preosteoblast cells (Osx+, Col1훼1+,
ALP+, and PTH-R1+ cells) are then maturing in osteoblasts.
On the one hand, this maturation is due to Wnt canonical
pathway. On the other hand, osteochondroblast progenitors
(Runx2+, Dlx5+, and Msx2+ cells) are able to secrete Ihh,
which induces PTHrp production. Both molecules partic-
ipate in preosteoblastic cell maturation. Mature osteoblast
expresses speci(c bone proteins such as osteocalcin (OSC),
bone sialoprotein (BSP), PTH-R1, and osteonectin [14].























































































Figure 2: Molecular regulation of MSCs during bone formation. (a) Ihh pathway: Indian hedgehog (Ihh) stimulates, directly or indirectly
(through the parathyroid hormone-related peptide (PTHrp) synthesis), chondrocytes proliferation and their di)erentiation into hypertrophic
or larger cells. Ihh binds to its receptor Patched (Ptch), which inhibits Smoothened (Smo). 'e resulting activation of Smo leads to an
increase of intracellular concentration of Gli proteins (Gli activator (GliA) and Gli repressor (GliR)) subsequent of the inhibition of their
degradation regulated by glycogen synthase kinase (GSK3훽), protein kinase A (PKA), and casein kinase (CSK). A*er translocation into the
nucleus, Gli activator could bind to its promoter and stimulate various genes’ expression, especially Runx2 [11, 12]. (b) PTH and PTHrp
pathway: parathyroid hormone (PTH) and parathyroid hormone-related (PTHrp) bind to PTH-receptor1 (PTHr1), which is a G protein-
coupled receptor that activates adenylate cyclase. 'is leads to cAMP production, PKA and PKC stimulation, and Runx2 expression. 'e
exact mechanism leading to Runx2 is still unknown. (c) BMP pathway: bone morphogenetic proteins (BMPs) binds to a tetrameric receptor
encompassing type I (BMPR1) and type II (BMPR2) receptors that are serine-threonine kinases. 'e receptor activation induces signal
transduction through Smads ormitogen-activated protein kinase (MAPK). Smads are cytoplasmicmolecules that are classi(ed into 3 subsets:
(1) receptor-regulated Smads (Smads 1, 2, 3, 5, and 8); (2) common-partner Smads (Smad 4); (3) inhibitory Smads (Smads 6, 7). Smads 1, 5,
and 8 are activated by phosphorylation induced by BMPs interacting with their receptors. Receptor-regulated phosphorylated Smads are then
able to form a dimeric complex with Smad 4 allowing its nuclear translocation. When phosphorylated, Smads 6 and 7 both inhibit Smads 1,
5, and 8 phosphorylation and Smad 4 linking [13]. In the nucleus, the dimeric Smad complex will induce the target genes expression such
as Runx2, distal-less homeobox 5 (Dlx5), and osterix (Osx) which are osteoblastic genes [14, 15]. (d)Wnt-훽 catenin canonical pathway: Wnt
molecules are involved in multiple cell functions, including osteogenesis. Wnt-1, Wnt-3a, Wnt-4, Wnt-5, Wnt-10b, and Wnt-13, are essential
in bone formation [16]. Wnt binds to its receptor Frizzled (Fzd) and coreceptor, low-density lipoprotein receptor-related protein (Lrp). In
absence of binding, dishevelled (Dsh) remains inactivated in the cytoplasm and 훽 catenin can form a complex with GSK3훽, adenomatous
polyposis coli (APC), and axin that leads to their degradation by ubiquitination.WhenWnt binds to its receptor, phosphorylated Dsh induces
axin and GSK3훽 inhibition and thus leads to 훽-catenin accumulation. 훽-Catenin is then able to translocate into the nucleus where it drives
the target genes expression. (e) MAPK pathway: mitogen-activated protein kinases (MAPKs) are able to phosphorylate and inhibit GSK3훽
and Smads 1, 5, and 8 activities.'ey are also able to induce Runx2 and Dlx5 expression. MAPK can be triggered by epithelial growth factor
(EGF), (broblast growth factor (FGF), and BMPs.
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Figure 3: Bone remodeling: (a) in precursor cell stage, the macrophage-colony stimulating factor (M-CSF) binds to its receptor (c-Fms). It
promotes survival and proliferation of osteoclast precursors, as well as RANK and c-Fos expression. (b) c-Fms pathway: M-CSF binds to c-Fms
and promotes cell proliferation and survival. It also promotes RANK and c-Fos expression as well as NFATc1 autoampli(cation through AP1.
(c)RANKpathway: the binding of RANKL to RANKpromotes the recruitment of tumor necrosis factor receptor-associated factor 6 (TRAF6),
which can activate the nuclear factor-휅B (NF-휅B) and mitogen-activated protein kinases (MAPKs), such as p38 and Jun N terminal kinase
(JNK). TRAF6-activated NF-휅B induces the expression of NFATc1, an important transcription factor for osteoclastogenesis. 'is NFATc1
expression is also stimulated by the nuclear factor of activated T cells cytoplasmic 2 (NFATc2). Finally, RANK also activates the tyrosine
kinases Btk and Tec that are involved in the phosphorylation of phospholipase C훾 (PLC 훾). NF-휅B can also stimulate the c-Fos induction. (d)
IgLRs pathway and calcium signaling: RANKactivation leads to phosphorylation ofDAP12 and FcR훾.'esemolecules are both associatedwith
IgLRs and stimulate Syk. Activated Btk/Tec/BLNK/SLP76 complex and Syk will phosphorylate PLC-훾which will mediate the calcium release
from intracellular stores. Calcium will activate calcineurin phosphatase which is involved in NFATC1 autoampli(cation. It also stimulates
C-Fos through CaMKIV activation. (e) NFATc1 autoampli%cation: by these three pathways, AP-1, calcineurin and NFATc1 participate in
NFATc1 autoampli(cation. Indeed, AP-1 and the continuous calcium signaling are essential for NFATc1 ampli(cation.'e NFATc1 promoter
is epigenetically activated through histone acetylation and contains NFAT binding sites. 'us, NFATc1 speci(cally autoregulates its own
promoter and is responsible for its robust induction. NFATc1 is negatively regulated by other transcription factors, such as IRF8, MafB, and
Bcl6 that are, in turn, inhibited by Blimp1, a transcriptional target of NFATc1.
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Based on all these molecular pathways, various therapeu-
tic approaches were investigated:
(i) Teriparatide and BMPs, as described below, were used
to stimulate the bone formation and to treat MRONJ
[41, 42].
(ii) Dickkopfs 1 (DKK1) is a natural Wnt-antagonist that
binds Lrp5/6. DKK1+/− mice show an increase in
all bone formation parameters [43]. By inhibiting
DKK1, another study has observed an increase of bone
density in a multiple myeloma mouse model [44].
(iii) Another study reported that MSCs gra* coupled
with lithium chloride treatment, a GSK3훽 inhibitor,
stimulates their di)erentiation into osteoblast in vivo
and in vitro [45].
(iv) Sclerostin is another Wnt-antagonist that binds
Lrp5/6, but in a di)erent region from DKK1. Li
et al. (2009) reported that antisclerostin antibody
treatment increases bone formation and bone mass
in a rat model of osteoporosis [46].
3.2. Molecular Signaling Controlling Bone Remodeling. Even
in adulthood, bone remains a highly dynamic organ in
constant remodeling. Two principal actors take part in bone
remodeling processes: (1) MSC-derived osteoblasts, which
promote bone formation and osteoclast, and (2) CD34+
hematopoietic progenitor-derived osteoblasts, which pro-
mote bone resorption.'e bone remodeling balance between
osteoformation and osteoresorption is regulated by several
cytokines.'e most characterized mechanism is the balance
between osteoprotegerin (OPG) and the Receptor Activator
of Nuclear Factor Kappa-B Ligand (RANKL), which are
both expressed and secreted by osteoblasts. As an autocrine
factor, RANKL binds to its transmembrane receptor (RANK)
present on preosteoclasts and osteoclasts and induces their
di)erentiation and activation, respectively. 'e balance is
due to OPG that binds to RANKL, blocking its interaction
with RANK and, thus, inhibiting the osteoclast maturation,
function, and survival.'e balance consequently tips towards
reducing bone resorption in presence of OPG [23]. Globally,
RANK activation leads to the expression and activation of
nuclear factor of activated T cells cytoplasmic 1 (NFATc1).'e
primordial and su4cient role of this transcription factor in
osteoclastogenesis has been demonstrated in vitro and in vivo
[47].
'e signaling pathway during osteoclastogenesis is based
on three receptors: c-Fms, RANK, and Immunoglobin-Like
Receptors (IgLRs) (OSCAR, PIR-A, SIRP훽1, and TREM 2),
as described in Figures 3(b)–3(e).
3.3. Molecular Signaling Controlling Osteoimmunology. Dur-
ing the last decade, the involvement of immunological cells
and cytokines in bone remodeling took a greater place.
For example, OPG is expressed by B cells and dendritic
cells [48]. RANKL is expressed by B cells, T cells, and훾훿-T cells, while RANK is expressed by macrophages and
monocytes [49]. Besides these examples of bone cytokines
playing a role in immune system, it was also demonstrated
that several immune cytokines could modulate the bone
biology: (1) important in,ammatory cytokines such as IL-1,
IL-6, and TNF-훼 stimulate RANKL expression and accelerate
bone destruction and (2) a variety of cytokines such as
IFN-훾, granulocyte/macrophage-colony stimulating factor
(GM-CSF), IL-4, and IL-10 were shown to stimulate bone
formation [50].
Unraveling bone homeostasis regulation allows for high-
lighting connections between bone remodeling and immune
cells. 'e role of T cells in osteoclastogenesis was more
speci(cally analyzed and summarized in Figure 4. Looking
at that (gure, we could conclude that '17 cells are the link
between bone destruction and the immune system. On the
other hand, if '17 are the immune cells responsible for
the stimulation of osteoclastogenesis, regulatory T cells or
Treg should be regarded as immune cells that stimulate bone
formation by downregulation of osteoresorption. Treg are
CD4+CD25+FOXP3+ cells that are specialized in tolerance,
immunity inhibition, autoimmune pathology prevention,
and regulation of in,ammation [51]. Treg also express speci(c
surface molecules including GITR and CTLA-4 [52]. Note-
worthily, FoxP3has been described as speci(c andmandatory
for the development and activity of Treg cells [53]. 'ese
cells are also known to secrete IL-10 and TGF-훽, which both
trigger reduction of in,ammation and bone destruction and
have an inhibitory e)ect on osteoclastogenesis [54]. However,
controversial studies reported that IL-10, IL-4, and TGF-훽
have the higher antiosteoclastic e)ects. Globally, TGF-훽, IL-
4, and IL-10 are potent antiosteoclastic cytokines, but further
studies are mandatory to understand their mechanisms of
action [55]. Treg cells are also known to inhibit osteoclastic
formation by a cell-to-cell contact via cytotoxic T lymphocyte
antigen 4 (CTLA4) [54].
Bisphosphonates are able to modify immune cell activ-
ities. 'is was particularly demonstrated with 훾훿-T cells.
'ese cells represent 5% of CD3+ T cells in human peripheral
blood and most of them belong to the V훾9V훿2 subset.'eir
name is based on the fact that they express a heterodimeric T
cell receptor (TCR) composed of 훾 and 훿 chains, in contrast
with the classic TCR, composed of 훼 and 훽 chains [56].'ese
cells were detected in rheumatoid arthritis patients and were
shown to be capable of secreting IL-17 and IFN-훾 according to
environmental cues [57]. It has also been demonstrated that
N-BPs such as Zoledronate could induce IFN-훾 production
by 훾훿 T cells in vitro and in vivo [19]. 'is activation is
likely to be due to the inhibition of farnesyl-diphosphate
synthase by N-BPs that would lead to the accumulation
of isopentenyl diphosphate and dimethylallyl diphosphate,
which are two agonists of V훾9V훿2-TCR [19]. 'erefore, 훾훿
T cell stimulation may potentiate the antiresorptive e)ects of
N-BPs.
In a recent study, Komatsu et al. (2014) [58] have unrav-
eled the link between'17 cells and Treg cells.'ey showed
that, in arthritic conditions, CD25+CD4+Foxp3+ T cells lost
FoxP3 expression and went through a “transdi)erentiation”
process into '17 cells, induced by the synovial (broblasts-
derived IL-6. 'ese ex-FoxP3 '17 cells had more pro-
nounced osteoclastic e)ects than na¨ıve CD4+T cell-derived
'17 cells.'ey were also characterized by the expression of
Stem Cells International 9




















Figure 4: Osteoimmunology: di)erentiation of osteoclast precursor into mature osteoclast. Synthesis of osteoblast, immune, and
mesenchymal cell action in osteoclastogenesis: (1) T helper cells type 1 ("1) that are playing a role in cellular immunity, are induced by IL-12,
and secrete IL-2 and INF-훾 (which has antiosteoclastogenic properties). (2) T helper cells type 2 ("2) are involved in humoral immunity.'ey
are induced by IL-4 and secrete IL-4 and IL-13. IL-4 has also antiosteoclastogenic properties. (3)"e T helper cell type 17 ("17) di)erentiates
from na¨ıve T CD4+ cells, has a proin,ammatory role, and is implicated into autoimmune disease.'17 is induced by TGF-훽, IL-6, IL-21, and
especially IL-23. '17 cells secrete IL-17, IL-21, and IL-22. IL-17 is a major in,ammatory cytokine and IL-21 stimulates '17 di)erentiation
and inhibits'1 and Treg cells actions. In osteoclastogenesis, IL-17 can produce and induce RANKL expression by osteoblast, a situation that
favors osteoresorption.'is is not the only stimulatory activity of'17 on osteoresorption as these cells express also higher levels of RANKL
compared to'1 and'2. Finally, they also have higher levels of IL-1, IL-6, and TNF-훼.
Sox4, CCR6, CCL20, IL-23 receptor (IL-23R), and RANKL
[58].
A new therapy for rheumatoid arthritis based on CTLA-
4 immunoglobulin underlined also the connection between
bone and immune system. On the one hand, CTLA-4
immunoglobulin was used to suppress immune responses
by targeting T lymphocyte activation antigens CD80/86 on
antigen-presenting cells and thus blocking the costimulation
[59]. On the other hand, Bozec and collaborators have shown
that CTLA-4 immunoglobulin induced the activation of
indoleamine 2,3-dioxygenase (IDO) in osteoclast precursors.
IDO is known to metabolize tryptophan, promote apoptosis,
and, therefore, decrease bone destruction [60].
Bone remodeling is also modulated in in,ammation and
during early responses of immune system. Toll-like receptors
2 (TLR2) and 4 (TLR4) activation by pathogen-associated
molecular patterns (PAMPs) or damage-associatedmolecular
patterns (DAMPs) in macrophages could stimulate TNF-훼
production and, thus, bone resorption [61].
Cathepsin K is a cysteine protease that is highly expressed
by osteoclasts. It degrades type I collagen, which is required to
adsorb calcium hydroxyapatite and leads to bone resorption
[62].'e cathepsinK-speci(c inhibitorNC-2300was initially
developed to suppress bone destruction, but it has also shown
anti-in,ammatory properties when tested in animal model
of rheumatoid arthritis. Indeed, cathepsin K participates in
TLR9 activation in dendritic cells and stimulated IL-6 and
IL-23 production [63]. A recent study used NC-2300 to treat
periapical lesion in a ratmodel and they observed a reduction
of in,ammation and bone destruction [64]. Odanacatib,
another cathepsin K inhibitor, has been developed for the
treatment of postmenopausal osteoporosis with encouraging
results [65].
4. Recent Advances in MRONJ Treatments
Treatments of MRONJ depend on multiple variables such
as age, sex, disease status, ONJ stage, comorbidities, and
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symptoms. Globally, two approaches are currently considered
in clinical practice: (1) conservative nonsurgical and (2) surgi-
cal procedures. Conservative management focuses on main-
taining optimal oral hygiene (home self-care and professional
dental care), elimination of active dental and periodontal
disease, topical antimicrobial mouth rinses (chlorhexidine
0.12%), and systemic antibiotic therapy. When required,
surgical therapy consists of a surgical debridement and/or
resection covered by a full-thickness mucoperiosteal ,ap.
Indeed, surgery provides pain control and infection control,
relieves so* tissue irritations, and decreases osteolysis [7,
66]. Beside these approaches, several treatments have been
developed and used to treat MRONJ:
(A) Teriparatide: as we previously mentioned, Teri-
paratide is a recombinant human parathyroid hor-
mone, which has stimulatory e)ects on osteoblasts
and osteoclasts and leads to an increase in bone
turnover and bone formation, as an osteoanabolic
agent [67]. 'is treatment has shown encouraging
results in MRONJ patients [30] and might be rec-
ommended in future years in osteoporotic patients
without cancer or radiation therapy, for a short-time
therapy. Indeed, preclinical studies demonstrated an
increased risk of osteosarcoma with long-term ther-
apy [67].
(B) Bone morphogenetic proteins (BMPs): another poten-
tial treatment concerns the use of bone morpho-
genetic proteins (BMPs), a subgroup of the trans-
forming growth factor-훽 (TGF-훽) family. BMPs are
implied in bone and cartilage formation during devel-
opment and growth [68]. Among them, BMP-2 and
BMP-7 are recognized as e)ective bone formation
inducers and have been approved by the Food and
Drug Administration (FDA) in 2001-2002 for this
therapeutic indication [69]. 'ey have been used in
orthopedics and oral/maxillofacial surgery, including
MRONJ [43]. In this clinical situation, BMP-2 was
delivered during surgery in the cleaned bone cavity,
inducing a successful healing of the necrotic area
and new bone formation. Unfortunately, BMPs could
exhibit important side e)ects such as in,ammation,
bone resorption, swelling, seroma, and carcinogenic
e)ects but these side e)ects could be dose-dependent
[69]. Nevertheless, future well-designed randomized
clinical trials are needed to ascertain the safety and
e4cacy of BMPs.
(C) Platelet concentrates: the use of autologous platelet
concentrate as a topical agent during bone resection
could also constitute a promising therapeutic strategy.
'ese concentrates are composed of human platelets
and are thus enriched in growth factors such as
platelet-derived growth factor (PDGF), transform-
ing growth factor-훽 (TGF-훽), vascular endothelial
growth factor (VEGF), and epidermal grow factor
(EGF) [70]. Dohan Ehrenfest et al. [71] de(ned four
groups of platelet concentrates based on their (brin
and leucocyte content: leucocyte and platelet-rich
(brin (L-PRF); leucocyte and platelet-rich plasma
(L-PRP); pure platelet-rich plasma (PRP); and pure
platelet-rich (brin (P-PRF). PRP is the most used
agent in the prevention and treatment of MRONJ
[72]. Nevertheless, L-PRF showed also promising
bene(ts [73] as leucocytes present in L-PRF can
address infection and regulate the immune sys-
tem [74] while physiological (brin matrix is easier
to manipulate during surgery and concentrate the
growth factors [75]. Autologous platelet concentrates
appear more and more to constitute a valuable
implementation for surgical procedures, although no
speci(c guidelines are available so far. 'e setup
of those guidelines is still restrained by the lack of
standardized parameters and biological properties
of these platelets concentrates, according to various
preparation techniques [76]. Another problem is to
keep theses factors at gra*ed site and, thus, the
treatment might be variable between patients.
(D) Platelet-derived growth factor-BB (PDGF-BB): plate-
let-derived growth factor-BB (PDGF-BB) is a new key
factor involved in angiogenesis and osteoformation.
It is secreted by preosteoclasts and promotes CD31+
and Emcn+ (Endomucin) vessel subtype formation,
as well as MSC and endothelial progenitor cell
migration [77]. Treatment with PDGF-BB has been
shown to increase vasculogenesis and bone formation
in ovariectomy-induced osteoporotic mouse model
[78]. 'is new molecule may constitute a new target
in bone resorptive pathology.
(E) Low-level laser therapy (LLLT) with Nd: YAG laser
or GaAlAs diode laser has been reported to be
useful in the treatment and prevention of MRONJ
in association with conservative and surgical man-
agement [79–81]. LLLT mechanism of action seems
to be photochemical: the photon energy absorbed is
converted into metabolic energy that will be used to
produce proteins and mitoses [82, 83]. LLLT provides
an improvement in vascularisation of mucous mem-
brane, bone regeneration, and pain reduction. It may
constitute a safe and e)ective adjunct therapy but it is
not recommended yet as a monotherapy.
(F) Hyperbaric oxygen (HBO) is an e)ective technique
mainly used in di4cult healing situation.'is healing
e)ect is attributed to the increasing oxygen concen-
tration, immunologic regulation, and reactive oxygen
species (ROS) and reactive nitrogen species (RNS)
production [84–86]. HBO gives a fast wound healing
and pain and swelling reduction in the treatment of
MORNJ [86–88]. A randomized controlled trial of
HBO therapy in MRONJ, by Freiberger et al. 2012,
came to the conclusion that HBO seems to be a useful
adjunct to ONJ treatment, especially in severe cases
[89].
(G) Medical ozone therapy (MOT) has been demonstrated
as antimicrobial, wound healing, vasculogenic, and
immunostimulating therapy [90, 91]. MOT acts by
preserving the endogenous antioxidant system and
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by blocking xanthine/xanthine oxidase system [91]. It
has been used as an adjuvant treatment in MRONJ
cases with a reduction of 90% of the symptoms and
the authors indicate that MOT is not a substitute of
recommended treatment [92, 93].
For the moment, all these new therapies are adjunctive
therapies. Likewise, due to the lack of data or the limited
number of studies, it is not possible to evaluate the real
e)ectiveness of those treatments. MRONJ remains a complex
and a none)ectively treatable disease. 'is situation could
be a direct consequence of the lack of molecular under-
standing that is mandatory in order to elaborate an e4cient
pharmacological agent. 'is could be the reason why MSCs
were investigated in multiple studies with a dual objective:
(1) cellular therapy and (2) a tool to identify new molecular
targets favoring the bone reconstruction in such a disease.
5. Mesenchymal Stem Cell Therapy in MRONJ
MSCs are multipotent stem cells that are increasingly used in
regenerative medicine. MSCs contribute actively to organo-
genesis during embryogenesis and, therea*er, to the main-
tenance of adult tissues. To be considered as MSCs, cells
must present three characteristics: (1) adherence to plastic
culture dishes; (2) expression of CD105, CD73, and CD90
but absence of expression of CD34, CD45, CD14 or CD11b,
CD79a or CD19, and HLA-DR markers; and (3) capacity to
di)erentiate into osteoblasts, chondrocytes, and adipocytes
[94]. In adulthood, MSCs are usually isolated from bone
marrow or adipose tissue but are also present in various
other tissues [95]. Due to their ability to di)erentiate into
osteocytes but most importantly due to the recent characteri-
zation of their immunomodulatory properties, MSCs should
strongly be regarded as gra*ingmaterial in osteonecrosis foci
[96].
5.1. Immunomodulatory E(ects of MSCs. 'ree di)erent cells
together constitute the innate immune system: natural killer
(NK) cells, dendritic cells (DCs), and macrophages. NK
cells are involved in antiviral or antitumoral defense and
are known to kill infected or tumor cells without MHC1
restriction [97]. MSCs are able to inhibit NK cells prolif-
eration by secreting indolamine 2,3-dioxygenase (IDO) and
prostaglandin E2 (PGE2) [98]. DC are antigen-presenting
cells that link the innate and adaptive immune system [99].
MSCs exert an inhibitory e)ect on dendritic cells (DCs)
di)erentiation through soluble factors (IL-6, PGE2) and cell-
to-cell contact [100, 101]. Macrophages are monocyte-derived
phagocytic cells that are basically divided into two categories:
M1 macrophages promote proin,ammatory reaction, and
M2 macrophages are rather involved in wound healing
[102]. 'ere is a temporal relation between M1 and M2
macrophages: in,ammatory M1 macrophages are predomi-
nant at early stages of tissue lesion and, later, wound healing
M2 macrophages become predominant. M1 macrophage
stage is necessary to clear dead tissue or infectious agents,
and M2macrophage stage allows the resolution of the injury
[103].'is balance between these two phenotypes constitutes
an important target in future therapies and can be in,uenced
by MSCs. Interestingly, MSCs support M2 macrophages
proliferation overM1macrophages by increasing IL-4 and IL-
13 levels and by decreasing TNF-훼 and IL-6 levels [104].
T cells and B cells are the actors of the adaptive immune
system. Although the e)ect of MSCs on B cells is still unclear,
some studies support that MSCs are able to inhibit B cell
di)erentiation and to decrease immunoglobulin production
[105]. However, those results are still questioned [106].
'e role of MSCs in modulating T cells depends on T
cell subtypes. MSCs are indeed able to inhibit cytotoxic T
lymphocyte proliferation and generate regulatory CD8+ cells
in coculture conditions [107]. It has also been demonstrated
that MSCs support regulatory T (Treg) cell proliferation by
secreting Il-10, PGE2, and TGF-훽 and by promoting the
expression of Foxp3 [108]. Globally, MSCs inhibit '1, '2,
and '17 proliferation. However, it has also been demon-
strated that gra*ing MSC could increase'2 activity in non-
'2-dominated autoimmunity and in allotransplant models
[109]. 'e exact mechanism by which MSCs suppress T
helper cell proliferation is poorly understood, but interesting
theories are rising up. Indeed, Sato et al. suggested that MSCs
secrete nitric oxide (NO), which would suppress STAT5
phosphorylation and T helper cell proliferation [110]. Meisel
et al. showed that IDO, which catalyzes the conversion
from tryptophan to kynurenine, was produced by MSCs and
could be a T cell inhibitory e)ector pathway [111]. Finally,
it is important to underline that, in those conditions, MSCs
needed to be previously activated by IFN-훾 to exert their
immunomodulatory e)ects which could also be linked to
their e)ects on in,ammation [106, 112].
5.2. "erapeutic E(ects of MSC in MRONJ. Several studies
exploited these interesting MSC-related immunomodulatory
e)ects in the treatment of MRONJ. MSC gra*s have been
performed in mice, pigs, and humans with encouraging
results [113–115]. Of note, the key of the success obtained with
MSCs seems to be more linked to their immunomodulatory
properties rather than their possible osteoblast di)erentia-
tion. Indeed, the e4cacy of MSC gra*s is dependent on their
capacity to decrease levels of IL-17, IL-6, c-reactive protein,
and '17 cells and to increase levels of IL-10, TGF-훽1, and
Treg cells [113, 114]. So, althoughMSCs are able to di)erentiate
into osteoblast precursors [100], there is no evidence that
gra*ed MSCs directly participate in bone regeneration by
osteoblast di)erentiation. Indeed, median survival of gra*ed
MSCs is about one or two weeks: this timeframe is not
consistent with a direct bone regeneration but is more related
to an indirect e)ect [116].Moreover, the absence of direct par-
ticipation of gra*ed MSCs in tissue regeneration by di)eren-
tiation has also been reported in various neurological diseases
models where gra*edMSCs did not last at the transplantation
site, despite their bene(cial e)ects on neuronal regeneration
[117]. All these observations led to the hypothesis that MSCs
bene(cial e)ects are due to their capacity to secrete cytokines
and/or growth factors, gathered under the term “secretome.”
Furthermore, from this point of view, this MSC secretome
should promote endogenous tissue regeneration, apoptosis
inhibition, and angiogenesis. 'erefore, MSC-conditioned
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culture medium has been injected into rat MRONJ-like
model, and full recovery was indeed observed in 63% cases.
Histological analyses showed that MSC secretome exhibits
anti-in,ammatory, osteogenic, angiogenic, and antiapoptotic
properties [118].
On the other hand, it has been demonstrated that the jaw
bone cells arise from cranial neural-crest stem cells (NCSCs)
[35]. Furthermore, using cell tracing or mapping strategies
[36], it has been recently demonstrated that jaw bone defects
are healed through neural-crest cell recruitment. Based on
these observations, gra*ing NCSCs or NCSC secretome in
MRONJ cases might be a new and relevant therapeutic strat-
egy to investigate. Interestingly, it was recently demonstrated
that adult bone marrow MSCs, but also adult adipose tissue
derived MSCs, are heterogeneous populations containing
NCSCs as well. 'e use of pure populations of MSCs or
NCSCs (or their respective secretomes) therefore deserves to
be considered in MRONJ animal models.
Altogether, although gra*ed MSCs/NCSCs are not
directly responsible for bone regeneration observed in
MRONJ animal models, they are suspected to recruit and
stimulate local or regional endogenous cells to di)erentiate
into osteoblasts and thus bone formation (1). Knowing the
bene(cial e)ect of gra*ed MSC in MRONJ, we can suggest
that MSC would have an impact on bone remodeling (2)
which is targeted by BPs and denosumab. As described
before, MSCs exhibit immunomodulatory properties (3) and
seem to decrease the in,ammation in MRONJ. In this con-
text, it would therefore be useful to recapitulate themolecular
regulatory events controlling osteogenic di)erentiation, bone
remodeling, and osteoimmunology.
6. Conclusions
Despite the recent advances in MRONJ pharmacological
treatments, we are still looking forward to a curative treat-
ment without dangerous side e)ects and an understanding of
MRONJ physiopathogenesis. During last decade, cell therapy
was considered to be e4cient for treating di)erent medical
conditions and, in this view, MSC gra*ing in MRONJ is a
recent therapeutic strategy that shows good results. However,
a*er (rst clinical trials, cell therapy of MRONJ using MSC
has to get back to the laboratory in order to understand
their e)ects, at the molecular and the cellular levels as little
information is available concerning the MSC mechanisms
of action. Research studies should therefore now focus on
the molecular mechanisms underlying the bene(cial e)ects
of MSC gra*s. Likewise, it is unclear if the major impact of
this cellular therapy is immunological or bone related. 'is
unclear situation is possibly related to the fact that MRONJ
is not a simple bone disease but could represent a model
of osteoimmunology pathology similar to what we observed
in rheumatoid arthritis. 'is could explain the absence of a
strictly de(ned treatment and a proper characterization of
MRONJ physiopathology.We strongly believe that a molecu-
lar dissection of gra*ed MSC e)ects in MRONJ would allow
us to get a better understanding of the physiopathological
sequences in this clinical situation but also to design new
pharmacological approaches to help patients.
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